Literature DB >> 21520010

Association of hepatocyte growth factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis.

Kana Hoshino1, Takashi Satoh, Yasushi Kawaguchi, Masataka Kuwana.   

Abstract

OBJECTIVE: To examine associations of single-nucleotide polymorphisms (SNPs) within genes for hepatocyte growth factor (HGF) and its receptor c-met with disease susceptibility and organ involvement in Japanese patients with systemic sclerosis (SSc).
METHODS: Four SNPs (HGF -1652 C/T, +44222 C/T, and +63555 G/T, and c-met -980 T/A) were analyzed in 159 SSc patients and 103 healthy control subjects with the use of a polymerase chain reaction-based assay. The influence of the HGF -1652 SNP on transcription activity was evaluated with a luciferase reporter assay and an electrophoretic mobility shift assay (EMSA).
RESULTS: There was no difference in the distribution of HGF/c-met SNPs between SSc patients and controls. HGF -1652 TT was found much more frequently in SSc patients with end-stage lung disease (ESLD) than in those without (41% versus 8%; P = 0.0004). This association was confirmed by a replication study involving a separate cohort of 155 SSc patients. Kaplan-Meyer analysis revealed that HGF -1652 TT carriers had a higher probability of developing ESLD than did CT or CC carriers. The HGF promoter carrying the HGF -1652 T allele had lower transcription activity than did the promoter carrying the C allele. EMSA showed the presence of a potential negative transcription regulator that binds specifically to the HGF promoter carrying a T allele at position -1652. Finally, TT carriers had a relative inability to increase circulating HGF levels even in the presence of advanced interstitial lung disease.
CONCLUSION: A SNP in the HGF promoter region may modulate the severity of interstitial lung disease by controlling the transcriptional efficiency of the HGF gene.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21520010     DOI: 10.1002/art.30415

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

1.  Genome-wide association study for endothelial growth factors.

Authors:  Wolfgang Lieb; Ming-Huei Chen; Martin G Larson; Radwan Safa; Alexander Teumer; Sebastian E Baumeister; Honghuang Lin; Holly M Smith; Manja Koch; Roberto Lorbeer; Uwe Völker; Matthias Nauck; Henry Völzke; Henri Wallaschofski; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Circ Cardiovasc Genet       Date:  2014-12-31

Review 2.  Genetics of scleroderma: implications for personalized medicine?

Authors:  Shervin Assassi; Timothy R D J Radstake; Maureen D Mayes; Javier Martin
Journal:  BMC Med       Date:  2013-01-11       Impact factor: 8.775

Review 3.  Racial differences between blacks and whites with systemic sclerosis.

Authors:  Richard M Silver; Galina Bogatkevich; Elena Tourkina; Paul J Nietert; Stanley Hoffman
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

Review 4.  Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature.

Authors:  Carmel J W Stock; Elisabetta A Renzoni
Journal:  Eur J Hum Genet       Date:  2018-02-23       Impact factor: 4.246

5.  A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis.

Authors:  Lara Bossini-Castillo; Carmen P Simeon; Lorenzo Beretta; Jasper C Broen; Madelon C Vonk; Raquel Ríos-Fernández; Gerard Espinosa; Patricia Carreira; María T Camps; Maria J Castillo; Miguel A González-Gay; Emma Beltrán; María del Carmen Freire; Javier Narváez; Carlos Tolosa; Torsten Witte; Alexander Kreuter; Annemie J Schuerwegh; Anna-Maria Hoffmann-Vold; Roger Hesselstrand; Claudio Lunardi; Jacob M van Laar; Meng May Chee; Ariane Herrick; Bobby Pc Koeleman; Christopher P Denton; Carmen Fonseca; Timothy Rdj Radstake; Javier Martin
Journal:  Arthritis Res Ther       Date:  2012-04-24       Impact factor: 5.156

6.  KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor.

Authors:  Lara Bossini-Castillo; Carmen P Simeon; Lorenzo Beretta; Jasper Broen; Madelon C Vonk; José Luis Callejas; Patricia Carreira; Luis Rodríguez-Rodríguez; Rosa García-Portales; Miguel A González-Gay; Ivan Castellví; María Teresa Camps; Carlos Tolosa; Esther Vicente-Rabaneda; María Victoria Egurbide; Annemie J Schuerwegh; Roger Hesselstrand; Claudio Lunardi; Jacob M van Laar; Paul Shiels; Ariane Herrick; Jane Worthington; Christopher Denton; Timothy R D J Radstake; Carmen Fonseca; Javier Martin
Journal:  Arthritis Res Ther       Date:  2012-12-27       Impact factor: 5.156

7.  The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects.

Authors:  Galina S Bogatkevich; Kristin B Highland; Tanjina Akter; Richard M Silver
Journal:  Pulm Med       Date:  2011-11-01

Review 8.  Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight).

Authors:  Hiroshi Furukawa; Shomi Oka; Kota Shimada; Naoyuki Tsuchiya; Shigeto Tohma
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-04-29

Review 9.  Genetic architecture of human fibrotic diseases: disease risk and disease progression.

Authors:  Agnès Gardet; Timothy S Zheng; Joanne L Viney
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

Review 10.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.